1 / 41

Drug used in disorders of coagulation

Drug used in disorders of coagulation. Vladimír Moravec, M.D. Mechanisms of blood coagulation. Trombogenesis: the platelet - white trombus - red trombus Hemostasis: 1.adhesion and activation of platelets 2.fibrin formation 3.vascular contraction. Blood coagulation. Two pathways:

kira
Download Presentation

Drug used in disorders of coagulation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Drug used in disorders of coagulation Vladimír Moravec, M.D.

  2. Mechanisms of blood coagulation • Trombogenesis: • the platelet - white trombus - red trombus • Hemostasis: • 1.adhesion and activation of platelets • 2.fibrin formation • 3.vascular contraction

  3. Blood coagulation • Two pathways: • 1.Intrinsic system • 2.Extrinsic system • Viz.Figure

  4. Monitoring of coagulation • 1. Extrinsic koagulo-pathways - components presents in plasma – aPTT • 2. Intrinsic koagulo-pathways – with participation of tishue components – • Prothrombin time (Quick test), • INR (International normalized ratio)

  5. Bleeding therapy • Haemostatics - local vasoconstriction • Antifibrinolytics- inhibit fibrinolysis • Antiaggregants – against platelets agregation • Fibrinolytics– rapidly lyse thrombus • Anticoagulants -blood coagulation

  6. 1. Haemostatic drugs • Somatostatin • Antithrombin III • Protamine sulfate, vitamin K - antidotum • Ethamsylate - facility of platelets agregation • Desmopressin, Terlipressin • Vasopresin, alfamimetics – vasoconstriction • Global efficacy : plasma, coagul. factors • Local efficacy: gelatin, collagen • Deficience of factors F. VIII., F. IX.

  7. Somatostatin • naturally occurring tetradecapeptide that produces numerous physiologic effects. • rapidly inactivated by peptidase enzymes; its plasma half-life is 1 to 3 minutes.

  8. Clinicalapplications • efficacy in a variety of clinical conditions, including carcinoid syndrome, enterocutaneous and pancreatic fistulas, the dumping syndrome, VIPomas, glucagonomas, diabetes mellitus, insulin excess in neonates, psoriasis, and short-bowel syndrome • its efficacy in upper gastrointestinal bleeding is controversial

  9. ANTITHROMBIN III • purified preparations of antithrombin III derived from human plasma. • Antithrombin III concentrate is primarily used for the prophylaxis and treatment of patients with congenital antithrombin III deficiency and disseminative intravascular coagulopathy.

  10. PROTAMINE SULFAT • strongly basic protein that is capable of neutralizing the effects of HEPARIN. • dose is 1 mg IV for every 100 units of HEPARIN remaining in the patient; doses of 50 mg should not be exceeded within a 10-minute period to decrease the risk of adverse effects; the dose is usually administered by intravenous bolus over 1 to 3 minutes, but a constant infusion over 30 minutes may also be given.

  11. 2. Pharmacology of the anticoagulantdrugs • 1.- Heparin X Protamin sulfat, Antitrombin III., LMWH, Fraxiparin • 2. - Warfarin X Vit K, Pelentan • Dicumarol, Phenprocoumon (6days)

  12. ANTICOAGULANTS 1. direct - Heparin (antidotum-Protamin sulfat), Antithrombin III., Low-molecula-weight-heparin(LMWH) , Heparinoids – (local)

  13. ANTICOAGULANTS • 2. indirect - Warfarin (antidotum Vit K), Pelentan

  14. Heparin • aktivation Antithrombin III. • Inhibition of thrombocyt agregation • Aktivation of lipoprotein lipase (hypolipidemic effect) • bolus 5-10 tis. m.j., 1 tis. J/hod, aPTT • Any size of heparin chain can inhibit the action of factor Xa by binding to antithrombin (AT) • In contrast, in order to inactivate thrombin (IIa), the heparin molecule must be long enough to bind both antithrombin and thrombin.

  15. LMWH Generic name: antiXa/IIa t 1/2 (hod) Dalteparin 2 : 1 119-139 sodium Nadroparin 3,2 : 1 132-162 calcium Enoxaparin 2,7 : 1 129-180 sodium Tinzaparin 1,9 : 1 111 sodium

  16. Hirudin In nature - Hirudo medicinalis Specific thrombin inhibitor from the leech. Now is prepared by recombinant DNA technology – lepirudin • selective inhibitor of thrombinu, • action is independent of ATIII. • Hirudin has litle effect on platelets or the bleeding time. APTT monitoring antidotum is not available

  17. Cumarine anticoagulants • Oral anticoagulants. • Block the carboxylation of several glutamate residues in prothrombin and factors VII, IX, X., and protein C.(endogenous anticoagulans) • antagonists of Vitamin K - f. VII, IX, X, • dicumarol - Etylbiskumacetate (Pelentan) • monocumarin - Warfarin , 1xd

  18. 3. Fibrinolytic drugs • Rapidly lyse thrombi by catalyzing plasmin protease from its precursor plasminogen. • Fibrin degradation • Administered by intravenous infusion (250 000 units, followed by 100 000 units/h • Indication: multiple pulmonary emboli, central deep venous thrombosis, acute myocardial infarction • Viz figure

  19. Fibrinolytics drugs • trombolytics 1. generation : streptokinase, urokinase – notselective, systemic fybrinolysis • trombolytics 2. generation: tissue plasminogen activators (tPA) with recombinant types: rt-PA Alteplase -is unmodified human t-PA. Antistreplase(ASPAC)- anisolated plasminogen streptokinase activator complex.

  20. Fibrinolytics drugs • Streptokinase is a protein synthetised by streptococci that combines with the plasminogen. This complex catalyzes the conversion of inactive plasminogen to active plasmin. • Urokinase is a human enzyme synth. By the kidney that directly converts to plasmin. • Antistreplase consists of a complex plasminogen and streptokinase that has been acylated to protect.

  21. FIBRINOLYTICS FIBRINOLYTICS Plasminogen Inhibition Activation Various stimuli + Blood proactivator Blood activator - + Antiactivators urokinase - + Streptokinase Activator + Proactivator Plasmin t-PA Anistreplase + + Thrombin Fibrin split products Degradation products Fibrinogen Fibrin

  22. Antifibrinolytics • Antidotum: Aprothinin, PAMBA, Etha aminokapronic acid.

  23. 4. Antitrombotic drugs: Drug that antagonize pathway interfere with platelet agregation in vitro and prolong the bleeding time in vivo.

  24. Platelet function is regulated • Platelet function is regulated by three categories of substances: • Contains agents generated within the platelet that interact with membrane receptors: • Catecholamines, collagen, thrombin, prostacyclin • ADP, prostaglandinD2, E2, serotonin • Paltelets within platelet: cAMP a cGMP, TxA2

  25. Antitrombotic - antiplatelet drugs • Representants: • Aspirin – inhibition of prostaglandine meetabolisme • Ticlopidin, Clopidogrel – inhibition of ADP-induced platelet aggregation • Dipyridamol • Abciximab – parenteral – blockade of GP 2b/3a

  26. Aspirin, ASA • Aspirin inhibits the synthesis of TxA by irreversible acetylation of the enzyme cyclooxygenase 2. The platelet canot manufacture new enzyme during its 10-day lifetime. • Prolong the bleeding time. • Studies were conducted to ëwaluate the use of aspirin for 4-5 years in the primary profylaxis of cardiovascular mortality. • Dosses?? 100-325 mg/day

  27. Ticlopidine • Reduce platelet aggregation by inhibiting the ADP pathways of platelets. • Adverse effects include nausea, dyspepsia, hemorage, leukopenia. • Dosage is 250 mg/twice day • Its useful in patients who cannot tolerate aspirin.

  28. Ticlopidin a Clopidogrel

  29. Ticlopidin - negatives?? • Adverse ractions: Granulocytopenie ( 2,4% cases). • Ticlopidin is more Expensive against aspirin.

  30. Abciximab • New class of platelet-inhibiting drug that blocks platelet receptors. • Is a mouse/human chimeric monoclonal antibody that blocks IIb/ IIIa receptors.

  31. 5. Drugs used in bleeding disorders • Vitamin K • Fibrinogen • Deficience of f. VIII., f. IX. • Fibrinolytic inhibitors: Aminocapronic acid, PAMBA, Aprothinin

  32. Thank you...

More Related